US drug costs are rising domestically while decreasing in other countries. The disparity in drug prices has prompted consideration of potential actions, with some reports suggesting that brand-name drug prices increase after launch in the US but fall abroad. The issue is being discussed in various contexts, including healthcare reform and international trade, with some focusing on the role of the pharmaceutical sector and others on the risks associated with foreign supply chains.